AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04438603 — intervention group
Intervention type: DRUG
Intervention: Intervention for patients at high risk of disease progression
Description: BP-lowering goal of \< 125/75 mm Hg and treat with steroids or steroids combined with immunosuppressants based on optimal supportive therapy:~1. If GFR>60 ml/min/1.73m\^2, oral prednisone 0.6-0.8 mg/kg/day ( (maximum dose 48 mg/day) for 2 months, followed by a monthly dose reduction of 8 mg for 24 weeks.~2. If GFR is 30-60 ml/min/1.73m\^2, intravenous cyclophosphamide (CTX) 750 mg per month per m\^2 for 6 months, along with oral prednisone (at the same dose as 1); if intravenous administration is unacceptable, then the above regimen was replaced with oral mycophenolate mofetil 500 mg bid for 24 weeks.
Study NCT00733356 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vyvanse
Description: Subjects will participate in an open-label dose optimization period and successful titration to an optimal dose of Vyvanse™, subjects will take their optimized dose of Vyvanse™ (30, 50 or 70 mg/day) during the week leading up to their final visit. During the study subjects will take their prescribed dose once a day in the morning with breakfast.
Study NCT01869491 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Compound Sodium Alginate Double Action Chewable Tablets
Description: 2 tablets four times daily
Study NCT01869491 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo tablets
Description: 2 tablets four times daily
Study NCT02253667 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HFONC
Study NCT02253667 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Conventional oxygen therapy
Study NCT03099369 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Daily Step-based Exercise
Description: A 12-week step-based exercise prescription with the eventual goal of walking at least 5,000 steps a day.
Study NCT03099369 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Symptom-based Exercise
Description: A 12-week symptom-based exercise prescription adapted from clinical practice guidelines.
Study NCT03099369 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fitbit Fitness Monitor
Description: Used by the experimental group to assess outcome and to guide exercise therapy; used by the active comparator group to assess outcome only
Study NCT03099369 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fitbit Fitness Monitor
Description: Used by the experimental group to assess outcome and to guide exercise therapy; used by the active comparator group to assess outcome only
Study NCT01257243 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Syrup of guaifenesin
Description: 5ml each 4 hours
Study NCT01451996 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Claritin
Description: Subject will be given 10mg Claritin tablet.
Study NCT02725164 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxygen concentration
Description: oxygen concentration will be measured in the tracheal tube and oropharynx during spontaneous or controlled ventilation
Study NCT02725164 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: oxygen concentration
Description: oxygen concentration will be measured in the tracheal tube and oropharynx during spontaneous or controlled ventilation
Study NCT02725164 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nitrous oxide concentration
Description: nitrous oxide concentration will be measured in the tracheal tube and oropharynx during spontaneous or controlled ventilation
Study NCT02725164 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: nitrous oxide concentration
Description: nitrous oxide concentration will be measured in the tracheal tube and oropharynx during spontaneous or controlled ventilation
Study NCT02725164 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carbon dioxide concentration
Description: carbon dioxide concentration will be measured from the tracheal tube and in the oropharynx during spontaneous or controlled ventilation
Study NCT02725164 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: carbon dioxide concentration
Description: carbon dioxide concentration will be measured from the tracheal tube and in the oropharynx during spontaneous or controlled ventilation
Study NCT02725164 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sevoflurane concentration
Description: sevoflurane concentration will be measured in the tracheal tube and oropharynx during spontaneous or controlled ventilation
Study NCT02725164 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sevoflurane concentration
Description: sevoflurane concentration will be measured in the tracheal tube and oropharynx during spontaneous or controlled ventilation
Study NCT03141216 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VCV+PSV
Description: invasive mechanical mechanical modes by volume cycling and by pressure support which the patients will be submitted to before weaning. Post-operative mechanical ventilation average time: 6 hours after ICU admission.
Study NCT03141216 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PCV+PSV
Description: invasive mechanical mechanical modes by pressure cycling and by pressure support which the patients will be submitted to before weaning. Post-operative mechanical ventilation average time: 6 hours after ICU admission.
Study NCT01900457 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: electromyography
Study NCT01900457 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: electroencephalography
Study NCT05704010 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Video capsule endoscopy
Description: Video capsule endoscopy every 2 years
Study NCT02697461 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intrinsic Foot Strengthening
Description: Intrinsic foot strengthening is a commonly used intervention in clinic used to increase foot stability both in prevention of and in treatment of foot and ankle injury. Subjects allocated to the strengthening program will be educated in commonly used short foot exercises and toe yoga maneuvers that target the intrinsic muscles of the foot. No equipment will be required to perform the exercises.
Study NCT04708119 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: The follicular tissues were also excised after tooth extraction.
Description: The follicular tissues were also excised after tooth extraction. Soft tissue samples taken during surgical removal of ILTM were evaluated in the department of pathology.
Study NCT04399837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spesolimab
Description: Solution for injection
Study NCT04399837 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solution for injection
Study NCT03143881 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: Standardized information on the etiology of HF, mechanisms and side effects of medications prescribed, strategies for minimizing exacerbations, and warning signs of worsening clinical status will be discussed with the patient.
Study NCT04623307 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Non-contact DCS-Speckle multi-parameter imaging
Description: The protocol consists of 2-min resting, 6-min stationary state and 2-min resting, with monitoring data continuously by the DCS-Speckle.
Study NCT02697461 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Joint Mobilization
Description: Joint mobilization is a commonly used clinical intervention used to decrease pain and increase joint range of motion. In the treatment groups who present with joint hypomobility, a forefoot inversion maneuver with a dorsally applied pressure in the lateral midfoot and rearfoot stabilized will be applied at the barrier before the physiologic end range of motion. A second mobilization will be performed at the distal segment of the 1st Tarsometatarsal joint. These mobilizations will be performed by a board certified orthopaedic physical therapist with 14-yrs of practice experience. No equipment will be required to perform the joint mobilization.
Study NCT01313026 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous nerve evaluation
Description: Implantation of a nerve stimulator to stimulate the sacral nerve plexus
Study NCT01013948 — intervention group
Intervention type: OTHER
Intervention: Non-Interventional
Description: Non-Investigational Product (Survey Study)
Study NCT00985855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin, vinorlebine, cetuximab
Description: patient will receive 2 cycles of cisplatine 80 mg/m² at day 29 and day 50 more vinorelbine 15 mg/m² at day 29, day 36 and day 50 and 57 associated to cetuximab 400 mg/m² at day: 22,29, 36, 43, 50, 57, 64 and 71
Study NCT00985855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatine, etoposide, cetuximab
Description: patient will receive 2 cycles of cisplatine 50 mg/m² at day 29, 36, 57, and 64 + étoposide 50mg/m² during day 29-33, day 57-61associated to cetuximab 400 mg/m² at day: 22,29, 36, 43, 50, 57, 64 and 71
Study NCT03022305 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group one - standard therapy
Description: Group two - standard physical therapy treatment for shoulder and hip maladjustment.
Study NCT03022305 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group two - neuromuscular therapy
Description: Use of physical therapy treatment for shoulder and hip maladjustment.
Study NCT00198341 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiological Arm
Description: Clinical Visit + X-Ray Chest
Study NCT00198341 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Scannographic arm
Description: Clinical visit + X-Ray Chest + CT-Scan + Fibroscopy (for squamous cell)
Study NCT03537768 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ulipristal Acetate
Description: UPA Tablet
Study NCT03537768 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levonorgestrel
Description: LNG Tablet
Study NCT03537768 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levonorgestrel
Description: LNG Tablet (x2)
Study NCT01643915 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: No distraction method
Description: Patients with conventional treatment. No distraction method during the treatment visits.
Study NCT01643915 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Distraction method
Description: Patients will see a cartoon film in a screen attached to the ceiling, just above the dental chair during the second treatment visit.
Study NCT01643915 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Distraction method
Description: Patients will see a cartoon film with with Rimax® multimedia eyeglasses that occlude the environment partially during the second treatment visit.
Study NCT04200859 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold application
Description: cold application using ice pack/gel pad in the control of pain experienced during chest tube removal
Study NCT04105361 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Posterior neurectomy
Description: Cut of posterior nasal nerve
Study NCT04501705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib Mesylate
Description: Apatinib mesylate tablets: Orally, 500 mg, once a day, with warm water for half an hour after a meal (the time of taking the medicine every day should be the same as possible).~Continue to use 28 days as a cycle, medication until disease progression (PD), intolerable toxicity occurs or the patient withdraws informed consent. However, the longest period does not exceed 24 cycles, and the treatment after 24 cycles is determined by the investigator.
Study NCT01713322 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pain management education
Description: Parents are provided with educational material on how to manage child pain during immunization.
Study NCT01713322 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: No pain management education
Description: Control - parents receive general information about childhood immunization.
Study NCT03242538 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pelvic Exercise
Description: Hip extension and external hip rotation exercises are completed prior to daily external beam radiation treatment.
Study NCT02545595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex 1 mg/kg
Study NCT02545595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex 2 mg/kg
Study NCT02545595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex 4 mg/kg
Study NCT00071994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gefitinib
Description: Given orally
Study NCT00071994 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT02115672 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BL-8040
Description: BL-8040 will be added to imatinib to improve CML response.
Study NCT03823482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Administration of lidocaine 2% 4 mg/kg administered as regional anesthesia of the scalp prior to Mayfield frame placement and lidocaine 1% 40 mg topically to the throat prior to direct laryngoscopy and endotracheal intubation.
Study NCT00945880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clemizole hydrochloride
Description: Two 50 mg capsules containing clemizole hydrochloride are to be administered orally twice a day for 28 days for a total daily dose of 200 mg. Followed immediately by standard of care treatment consisting of interferon and ribavirin
Study NCT01913223 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nestis® jet injector system with a bi-functional catheter
Study NCT01155505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide (CC-5013)
Description: CC-5013 given PO daily on D1-D14 every 21 days and Paclitaxel administered IV over 1 hour on d1 and 8 every 21 days until tumor progression or unacceptable toxicity
Study NCT02225769 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Management of febrile children using e-POCT
Description: Use of the e-POCT tool by study clinicians for the clinical management of febrile episodes. The e-POCT tool is an electronic algorithm that integrates key clinical elements with the results of malaria and host biomarkers point-of-care test results (including oximetry).
Study NCT02225769 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Management of febrile children using ALMANACH
Description: Management of febrile children by study clinicians using ALMANACH. ALMANACH is an improved IMCI algorithm on mobile phone or tablet
Study NCT02082782 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Irreversible electroporation (IRE)
Description: Percutaneous (CT-guided) or open (US-guided) irreversible electroporation of central colorectal liver metastasis.
Study NCT01157494 — intervention group
Intervention type: OTHER
Intervention: classification of hand manipulation function
Description: To determine the criterion validity of the classification of the pattern of manipulation proposed by Ferrari et al. we correlated hand manipulation classes with both the scores of the two standard criteria chosen (AHA and Melbourne Assessment).
Study NCT01965951 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computerized Plasticity-based Adaptive Cognitive Training
Description: Computerized Plasticity-based Adaptive Cognitive Training requiring a total maximum of 39 treatment sessions, 4-5 times weekly, \~30 mins each session.
Study NCT01965951 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Commercially available computerized training
Description: Commercially available computerized training requiring a total maximum of 39 treatment sessions, 4-5 times weekly, \~30 mins each session.
Study NCT00684294 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TGFβ2 Antisense-GMCSF Gene Modified Autologous Tumor Cell (TAG) Vaccine
Description: Patients with solid tumors will receive TAG Vaccine 1 x 10\^7 cells/ injection or TAG Vaccine 2.5 X 10\^7 cells/injection once a month for up to 12 doses via intradermal injection as long as sufficient material is available. Selection of cohort is dependent on the amount of tumor cell yield following harvest and processing.
Study NCT02144337 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Steps To Active Kids (STAK) programme
Description: Intervention described in Arm/Group Description.
Study NCT01435642 — intervention group
Intervention type: OTHER
Intervention: No treatment given
Description: Subject will fill out a questionnaire when entering the non-interventional study
Study NCT03684785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cavrotolimod
Description: Intratumorally dosed cavrotolimod.
Study NCT03684785 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab dosing as per the US prescribing information.
Study NCT02905656 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Brief Advice
Description: Psychoeducation
Study NCT02905656 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Description: Guides participants toward choosing to make a change in their behavior with a collaborative conversation.
Study NCT03684785 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: Cemiplimab dosing as per the US prescribing information.
Study NCT03684785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cavrotolimod
Description: Subcutaneously dosed cavrotolimod
Study NCT02905656 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rate Reduction
Description: Reducing the number of cigarettes consumed.
Study NCT02905656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pharmacological
Description: Nicotine Replacement Therapy in the form of gum.
Study NCT02905656 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MI+RR
Description: Combination of reducing the number of cigarettes consumed while guiding the participant to make a change in their behavior.
Study NCT00352443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Description: part 1: dose assigned by ETx online system PO days 1-28 daily part 2: cohort a: 5 mg PO days 1-28 part 2: cohort a: 1250 mg PO days 8-28 (cycle 1) days 1-28 (subsequent cycles)
Study NCT00352443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib ditosylate
Description: dose assigned by ETx online system PO days 1-28 daily part 2 cohort a: 1250 mg PO d 8-28 (cycle 1) days 1-28 (subsequent cycles) part 2 cohort b: 120 mg PO days 1-28 daily
Study NCT04723901 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dual target CAR-T cell therapy
Description: CD19/CD22 dual target CAR-T cell therapy
Study NCT02462174 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: 0.5 mg/ kg ketamine with bupivacaine by caudal route after anesthesia and before start of surgery.
Study NCT02462174 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: 0.5 mg/ kg ketamine with bupivacaine will be sprayed around the spermatic cord before wound closure.
Study NCT02462174 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: 1 ml/kg bupivacaine 0.25% (maximum volume = 20 ml) by caudal route
Study NCT02462174 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: 0.3 ml/kg bupivacaine 0.25% will be sprayed around the spermatic cord before wound closure
Study NCT01464294 — intervention group
Intervention type: DEVICE
Intervention: Milled ceramic restorations
Description: Restoration of back teeth with milled ceramic crowns or onlays
Study NCT01464294 — intervention group
Intervention type: DEVICE
Intervention: Milled nano-composite restorations
Description: Restoration of back teeth with milled crowns or onlays
Study NCT01900457 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: approaches from psychophysics
Study NCT02406950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: The brachial FMD before and after IR injury will be assessed. After randomization, study medication will be treated. In 2 hours later, the brachial FMD before and after IR injury will be assessed again. All volunteers had a wash-out period of 7 days. Seven days later, the subjects returned to crossover study medication (ie, sitagliptin or placebo), and the protocol described above was repeated.
Study NCT02406950 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Sitagliptin
Description: The brachial FMD before and after IR injury will be assessed. After randomization, study medication will be treated. In 2 hours later, the brachial FMD before and after IR injury will be assessed again. All volunteers had a wash-out period of 7 days. Seven days later, the subjects returned to crossover study medication (ie, sitagliptin or placebo), and the protocol described above was repeated.
Study NCT03799211 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Description: Phone call using motivational interviewing technique
Study NCT03799211 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: will receive a regular study phone call after three months